Department of Surgery, Nancy-Brabois Hospital, Faculty of Medicine, University of Nancy, Nancy, France.
Am J Surg. 2010 Oct;200(4):435-9. doi: 10.1016/j.amjsurg.2009.11.009. Epub 2010 Apr 20.
Radiofrequency ablation (RFA) of liver tumors is associated with a risk of incomplete ablation or local recurrence.
One hundred sixty-eight patients with 311 unresectable liver tumors were included. Effects of different variables on incomplete ablation and local recurrence were analyzed.
There were 132 hepatocellular carcinomas and 179 liver metastases. Tumor size was 24 (±13) mm. Two hundred twenty-six tumors were treated percutaneously, and 85 through open approach (associated with liver resection in 42 cases). There was no mortality. Major morbidity rate was 7%. Incomplete ablation and local recurrence rates were 14% and 18.6%. Follow-up was 29 months. On multivariate analysis, factors associated with incomplete ablation were tumor size (>30 mm vs ≤30 mm, P = .004) and approach (percutaneous vs open, P = .0001). Factors associated with local recurrence were tumor size (>30 mm vs ≤30 mm, P = .02) and patient age (>65 years vs ≤65 years, P = .05).
RFA is effective to treat unresectable liver tumors. However, there is a risk of incomplete ablation when percutaneously treating tumors >30 mm. When tumor ablation is completely achieved, the main factor associated with local recurrence is tumor size >30 mm.
射频消融(RFA)治疗肝肿瘤存在不完全消融或局部复发的风险。
共纳入 168 例 311 个不可切除的肝肿瘤患者。分析了不同变量对不完全消融和局部复发的影响。
有 132 例肝细胞癌和 179 例肝转移瘤。肿瘤大小为 24(±13)mm。226 个肿瘤经皮治疗,85 个经剖腹手术治疗(其中 42 例与肝切除术相关)。无死亡病例。主要并发症发生率为 7%。不完全消融和局部复发率分别为 14%和 18.6%。随访 29 个月。多因素分析显示,不完全消融的相关因素是肿瘤大小(>30mm 与≤30mm,P=0.004)和治疗途径(经皮与剖腹,P=0.0001)。局部复发的相关因素是肿瘤大小(>30mm 与≤30mm,P=0.02)和患者年龄(>65 岁与≤65 岁,P=0.05)。
RFA 是治疗不可切除肝肿瘤的有效方法。然而,经皮治疗>30mm 的肿瘤时存在不完全消融的风险。当肿瘤完全消融时,与局部复发相关的主要因素是肿瘤大小>30mm。